These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

401 related items for PubMed ID: 24889275

  • 1. Usefulness and safety of oral cryotherapy in the prevention of oral mucositis after conditioning regimens with high-dose melphalan for autologous stem cell transplantation for lymphoma and myeloma.
    Batlle M, Morgades M, Vives S, Ferrà C, Oriol A, Sancho JM, Xicoy B, Moreno M, Magallón L, Ribera JM.
    Eur J Haematol; 2014 Dec; 93(6):487-91. PubMed ID: 24889275
    [Abstract] [Full Text] [Related]

  • 2. Icing oral mucositis: Oral cryotherapy in multiple myeloma patients undergoing autologous hematopoietic stem cell transplant.
    Chen J, Seabrook J, Fulford A, Rajakumar I.
    J Oncol Pharm Pract; 2017 Mar; 23(2):116-120. PubMed ID: 26684614
    [Abstract] [Full Text] [Related]

  • 3. Prospective oral mucositis audit: oral mucositis in patients receiving high-dose melphalan or BEAM conditioning chemotherapy--European Blood and Marrow Transplantation Mucositis Advisory Group.
    Blijlevens N, Schwenkglenks M, Bacon P, D'Addio A, Einsele H, Maertens J, Niederwieser D, Rabitsch W, Roosaar A, Ruutu T, Schouten H, Stone R, Vokurka S, Quinn B, McCann S, European Blood and Marrow Transplantation Mucositis Advisory Group.
    J Clin Oncol; 2008 Mar 20; 26(9):1519-25. PubMed ID: 18268357
    [Abstract] [Full Text] [Related]

  • 4. Oral mucositis in myeloma patients undergoing melphalan-based autologous stem cell transplantation: incidence, risk factors and a severity predictive model.
    Grazziutti ML, Dong L, Miceli MH, Krishna SG, Kiwan E, Syed N, Fassas A, van Rhee F, Klaus H, Barlogie B, Anaissie EJ.
    Bone Marrow Transplant; 2006 Oct 20; 38(7):501-6. PubMed ID: 16980998
    [Abstract] [Full Text] [Related]

  • 5. Oral mucositis and outcomes of autologous hematopoietic stem-cell transplantation following high-dose melphalan conditioning for multiple myeloma.
    Vera-Llonch M, Oster G, Ford CM, Lu J, Sonis S.
    J Support Oncol; 2007 May 20; 5(5):231-5. PubMed ID: 17564153
    [Abstract] [Full Text] [Related]

  • 6. The risk factors for oral mucositis and the effect of cryotherapy in patients after the BEAM and HD-l-PAM 200 mg/m(2) autologous hematopoietic stem cell transplantation.
    Vokurka S, Bystricka E, Scudlova J, Mazur E, Visokaiova M, Vasilieva E, Brandejsova R, Chvojkova I, Vrabcova M, Vitkova J, Mjartanova D, Vodickova M, Bockova J, Streinerova K.
    Eur J Oncol Nurs; 2011 Dec 20; 15(5):508-12. PubMed ID: 21310656
    [Abstract] [Full Text] [Related]

  • 7. A Phase IIb, Multicenter, Open-Label, Safety, and Efficacy Study of High-Dose, Propylene Glycol-Free Melphalan Hydrochloride for Injection (EVOMELA) for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation.
    Hari P, Aljitawi OS, Arce-Lara C, Nath R, Callander N, Bhat G, Allen LF, Stockerl-Goldstein K.
    Biol Blood Marrow Transplant; 2015 Dec 20; 21(12):2100-2105. PubMed ID: 26327631
    [Abstract] [Full Text] [Related]

  • 8. Efficiency of supersaturated calcium phosphate mouth rinse treatment in patients receiving high-dose melphalan or BEAM prior to autologous blood stem cell transplantation: a single-center experience.
    Waśko-Grabowska A, Rzepecki P, Oborska S, Barzał J, Gawroński K, Młot B, Szczylik C.
    Transplant Proc; 2011 Oct 20; 43(8):3111-3. PubMed ID: 21996239
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. The Prospective Oral Mucositis Audit: relationship of severe oral mucositis with clinical and medical resource use outcomes in patients receiving high-dose melphalan or BEAM-conditioning chemotherapy and autologous SCT.
    McCann S, Schwenkglenks M, Bacon P, Einsele H, D'Addio A, Maertens J, Niederwieser D, Rabitsch W, Roosaar A, Ruutu T, Schouten H, Stone R, Vorkurka S, Quinn B, Blijlevens N, EBMT Mucositis Advisory Group.
    Bone Marrow Transplant; 2009 Jan 20; 43(2):141-7. PubMed ID: 18776926
    [Abstract] [Full Text] [Related]

  • 11. Efficacy of cryotherapy associated with laser therapy for decreasing severity of melphalan-induced oral mucositis during hematological stem-cell transplantation: a prospective clinical study.
    de Paula Eduardo F, Bezinelli LM, da Graça Lopes RM, Nascimento Sobrinho JJ, Hamerschlak N, Correa L.
    Hematol Oncol; 2015 Sep 20; 33(3):152-8. PubMed ID: 24519448
    [Abstract] [Full Text] [Related]

  • 12. A prospective, randomized study of cryotherapy during administration of high-dose melphalan to decrease the severity and duration of oral mucositis in patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation.
    Lilleby K, Garcia P, Gooley T, McDonnnell P, Taber R, Holmberg L, Maloney DG, Press OW, Bensinger W.
    Bone Marrow Transplant; 2006 Jun 20; 37(11):1031-5. PubMed ID: 16633359
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Veno-occlusive disease of the liver after high-dose cytoreductive therapy with busulfan and melphalan for autologous blood stem cell transplantation in multiple myeloma patients.
    Carreras E, Rosiñol L, Terol MJ, Alegre A, de Arriba F, García-Laraña J, Bello JL, García R, León A, Martínez R, Peñarrubia MJ, Poderós C, Ribas P, Ribera JM, San Miguel J, Bladé J, Lahuerta JJ, Spanish Myeloma Group/PETHEMA.
    Biol Blood Marrow Transplant; 2007 Dec 20; 13(12):1448-54. PubMed ID: 18022574
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Caphosol(®) mouthwash gives no additional protection against oral mucositis compared to cryotherapy alone in stem cell transplantation. A pilot study.
    Svanberg A, Öhrn K, Birgegård G.
    Eur J Oncol Nurs; 2015 Feb 20; 19(1):50-3. PubMed ID: 25224595
    [Abstract] [Full Text] [Related]

  • 19. A phase I dose-escalation trial of high-dose melphalan with palifermin for cytoprotection followed by autologous stem cell transplantation for patients with multiple myeloma with normal renal function.
    Abidi MH, Agarwal R, Tageja N, Ayash L, Deol A, Al-Kadhimi Z, Abrams J, Cronin S, Ventimiglia M, Lum L, Ratanatharathorn V, Zonder J, Uberti J.
    Biol Blood Marrow Transplant; 2013 Jan 20; 19(1):56-61. PubMed ID: 22892551
    [Abstract] [Full Text] [Related]

  • 20. The incidence of severe oral mucositis in patients undergoing different conditioning regimens in haematopoietic stem cell transplantation.
    Nakagaki M, Kennedy GA, Gavin NC, Clavarino A, Whitfield K.
    Support Care Cancer; 2022 Nov 20; 30(11):9141-9149. PubMed ID: 36008731
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.